Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

CONCLUSION: In this model-based simulation, switching from approved maintenance doses of semaglutide or dulaglutide to tirzepatide, even at the lowest approved maintenance dose of 5 mg, showed the potential to further improve HbA1c and body weight reductions.PMID:38407177 | DOI:10.1080/03007995.2024.2322072

Source: Current Medical Research and Opinion - February 26, 2024 Category: Research Authors: Shweta Urva Joshua A Levine Karen Schneck Cheng Cai Tang Source Type: research